163 related articles for article (PubMed ID: 8562141)
1. Thymidylate synthase inhibition, a dead end?
Herrmann R
Eur J Cancer; 1995 Nov; 31A(12):1919-20. PubMed ID: 8562141
[No Abstract] [Full Text] [Related]
2. Colorectal cancer--is there an alternative to 5-FU?
Bleiberg H
Eur J Cancer; 1997 Apr; 33(4):536-41. PubMed ID: 9274432
[No Abstract] [Full Text] [Related]
3. [Raltitrexed in colorectal cancer].
Comandone A; Oliva C; Dal Canton O; Boglione A; Bergnolo P
Tumori; 2001; 87(1 Suppl 1):S53-4. PubMed ID: 11300026
[No Abstract] [Full Text] [Related]
4. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
5. Results of a European multicentre trial of Tomudex versus 5-FU/high dose LV (Machover regimen).
Cocconi G
Tumori; 1997; 83(1 Suppl):S72. PubMed ID: 9154075
[No Abstract] [Full Text] [Related]
6. The potential role of Tomudex in the treatment of advanced colorectal cancer.
Sobrero AF
Tumori; 1997; 83(2):576-80. PubMed ID: 9226024
[TBL] [Abstract][Full Text] [Related]
7. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
Kempin S; Gutierrez J; Wilson E; Lowery C; Diasio R
Cancer Invest; 2002; 20(7-8):992-5. PubMed ID: 12449732
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
Cunningham D
Tumori; 1997; 83(1 Suppl):S70-1. PubMed ID: 9154074
[No Abstract] [Full Text] [Related]
9. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Cunningham D; Zalcberg JR; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G
Eur J Cancer; 1995 Nov; 31A(12):1945-54. PubMed ID: 8562146
[TBL] [Abstract][Full Text] [Related]
10. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Jerusalem G; Bours V; Fillet G
Rev Med Liege; 1998 Jun; 53(6):318-21. PubMed ID: 9713208
[TBL] [Abstract][Full Text] [Related]
11. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
12. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Gunasekara NS; Faulds D
Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials referral resource. Clinical trials with tomudex.
Sorensen JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 Jul; 10(7):1041-2. PubMed ID: 8837120
[No Abstract] [Full Text] [Related]
14. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
15. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
16. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.
Jackman AL; Farrugia DC; Gibson W; Kimbell R; Harrap KR; Stephens TC; Azab M; Boyle FT
Eur J Cancer; 1995; 31A(7-8):1277-82. PubMed ID: 7577036
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Rustum YM; Harstrick A; Cao S; Vanhoefer U; Yin MB; Wilke H; Seeber S
J Clin Oncol; 1997 Jan; 15(1):389-400. PubMed ID: 8996166
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
19. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Köhne CH; Thuss-Patience P; Friedrich M; Daniel PT; Kretzschmar A; Benter T; Bauer B; Dietz R; Dörken B
Br J Cancer; 1998 Mar; 77(6):973-7. PubMed ID: 9528843
[TBL] [Abstract][Full Text] [Related]
20. Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
Punt CJ
Semin Oncol; 2000 Oct; 27(5 Suppl 10):88-90. PubMed ID: 11049038
[No Abstract] [Full Text] [Related]
[Next] [New Search]